Influence of related donor age on outcomes after peripheral blood stem cell transplantation

Cytotherapy

Volumn 14, Issue 6, 2012, Pages 707-715

  Richa, Elie M ^a   Kunnavakkam, Rangesh ^a   Godley, Lucy A ^a   Kline, Justin ^a   Odenike, Olatoyosi ^a   Larson, Richard A ^a   Nguyen, Vu ^a   Stock, Wendy ^a   Wickrema, Amittha ^a   Besien, Koen Van ^a   Artz, Andrew S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Older age; Recipients; Related donors; Transplant outcomes

Indexed keywords

CD34 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CELL MOTILITY; CRYOPRESERVATION; DONOR; DONOR AGE; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONRELAPSE MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

EID: 84862181188     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2012.681041     Document Type: Article

References (32)

1. Artz AS. Comorbidity and beyond: pre-transplant clinical assessment. Bone Marrow Transplant. 2005;36:473-4. (Pubitemid 43118139)
2. + cell counts and on the collection of peripheral blood stem cells. Transfusion. 1996; 36:601-10. (Pubitemid 26256427)
3. Bolan CD, Hartzman RJ, Perry EH, Trainor L, Miller J, Miller R, et al. Donation activities and product integrity in unrelated donor allogeneic hematopoietic transplantation: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant. 2008;14:23-8.
4. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001; 344:175-81. (Pubitemid 32064138)
5. ollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98: 2043-51.
6. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110:4576-83. (Pubitemid 351377826)
7. Dominietto A, Lamparelli T, Raiola AM, Van Lint MT, Gualandi F, Berisso G, et al. Transplant-related mortality and long-term graft function are signifi cantly infl uenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood. 2002;100:3930-4. (Pubitemid 35396857)
8. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood. 2001;98:2900-8.
9. Suzuya H, Watanabe T, Nakagawa R, Watanabe H, Okamoto Y, Onishi T, et al. Factors associated with granulocyte colonystimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang. 2005;89:229-35. (Pubitemid 41641103)
10. de Lavallade H, Ladaique P, Lemarie C, Furst S, Faucher C, Blaise D, et al. Older age does not infl uence allogeneic peripheral blood stem cell mobilization in a donor population of mostly white ethnic origin. Blood. 2009;113: 1868-9.
11. Richa E, Papari M, Allen J, Martinez G, Wickrema A, Anastasi J, et al. Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2009;15:1394-9.
12. Vasu S, Leitman SF, Tisdale JF, Hsieh MM, Childs RW, Barrett AJ, et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood. 2008;112:2092-100.
13. Bittencourt H, Rocha V, Chevret S, Socie G, Esperou H, Devergie A, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002;99:2726-33. (Pubitemid 34525358)
14. + cell dose. Blood. 2009;114:2606-16.
15. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R, et al. CD34 cell dose in granulocyte colonystimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood. 2001;98:3221-7.
16. Buckner CD, Clift RA, Sanders JE, Stewart P, Bensinger WI, Doney KC, et al. Marrow harvesting from normal donors. Blood. 1984;64:630-4. (Pubitemid 14073480)
17. Kim DH, Jamal N, Saragosa R, Loach D, Wright J, Gupta V, et al. Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. Biol Blood Marrow Transplant. 2007;13:1233-43. (Pubitemid 47413022)
18. van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23: 5728-38.
19. O' D onnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, et al. Phase I study of dose-escalated busulfan with fl udarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010; 51:2240-9.
20. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15: 825-8.
21. Peto R, Peto J. Asymptotically effi cient rank invariant test procedures (with discussion). J Royal Stat Soc Series A. 1972;135:185-206.
22. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in fi rst complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010; 28:1878-87.
23. Lysak D, Koza V, Jindra P. Factors affecting PBSC mobilization and collection in healthy donors. Transfus Apher Sci. 2005;33:275-83. (Pubitemid 41586193)
24. Cao TM, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, et al. CD34, CD4, and CD8 cell doses do not infl uence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol. 2005;33: 279-85. (Pubitemid 40261309)
25. + peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLAidentical sibling transplantation. Leukemia. 2003;17: 869-75. (Pubitemid 36626313)
26. + cell dose on the outcome of patients undergoing reduced-intensityconditioning allogeneic peripheral blood stem cell transplantation. Blood. 2003;102: 1108-1113. (Pubitemid 36917813)
27. + cell dose and outcome of patients undergoing reduced-intensityconditioning allogeneic peripheral blood stem cell transplantation. Leuk Lymphoma. 2005;46:177-83. (Pubitemid 40185946)
28. Friedman JS, Alpdogan O, van den Brink MR, Liu C, Hurwitz D, Boyd A, et al. Increasing T-cell age reduces effector activity but preserves proliferative capacity in a murine allogeneic major histocompatibility complex-mismatched bone marrow transplant model. Biol Blood Marrow Transplant. 2004;10:448-60. (Pubitemid 38771999)
29. + CD25 high regulatory T cells increases with age. Clin Exp Immunol. 2005;140:540-6. (Pubitemid 40813966)
30. Panse JP, Heimfeld S, Guthrie KA, Maris MB, Maloney DG, Baril BB, et al. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol. 2005;128:659-67. (Pubitemid 40343236)
31. Pang WW, Price EA, Sahoo D, Beerman I, Maloney WJ, Rossi DJ, et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci USA. 2011;108:20012-7.
32. Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2010;28:405-11.